TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Avricore Health ( (TSE:AVCR) ) is now available.
Avricore Health Inc. announced the expansion of its HealthTab™ platform into North Central London, marking the second NHS Integrated Care Board to join this initiative. The expansion, which took place on July 10, 2025, aims to address health inequalities through cholesterol screening in underserved populations. This initiative is part of the UK’s broader strategy to transform community pharmacies into hubs for chronic disease prevention and management, enhancing healthcare accessibility and effectiveness.
Spark’s Take on TSE:AVCR Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCR is a Neutral.
Avricore Health’s strong financials and strategic corporate developments are offset by high valuation concerns and neutral technical indicators. The company’s financial stability and growth potential are promising, but profitability and valuation require attention.
To see Spark’s full report on TSE:AVCR stock, click here.
More about Avricore Health
Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies to advance pharmacy practice and patient care. Its flagship offering, HealthTab™, aims to create the world’s largest network of rapid testing devices in community pharmacies, making actionable health information more accessible.
Average Trading Volume: 66,524
Technical Sentiment Signal: Sell
Current Market Cap: C$8.1M
For detailed information about AVCR stock, go to TipRanks’ Stock Analysis page.